Model-Informed Drug Development, Pharmacokinetic/Pharmacodynamic Cutoff Value Determination, and Antibacterial Efficacy of Benapenem against Enterobacteriaceae

Benapenem is a novel carbapenem. The objective of this study was to determine the pharmacokinetic (PK)/pharmacodynamic (PD) cutoff values and evaluate the optimal administration regimens of benapenem for the treatment of bacterial infections via PK/PD modeling and simulation. Ertapenem was used as a control. Infected mice received an intravenous (i.v.) injection of benapenem or ertapenem of 14.6, 58.4, or 233.6 mg/kg of body weight, and the PK/PD profiles were evaluated. ABSTRACT Benapenem is a novel carbapenem. The objective of this study was to determine the pharmacokinetic (PK)/pharmacodynamic (PD) cutoff values and evaluate the optimal administration regimens of benapenem for the treatment of bacterial infections via PK/PD modeling and simulation. Ertapenem was used as a control. Infected mice received an intravenous (i.v.) injection of benapenem or ertapenem of 14.6, 58.4, or 233.6 mg/kg of body weight, and the PK/PD profiles were evaluated. The MICs were determined by using a 2-fold agar dilution method. Mathematical models were developed to characterize the pharmacokinetic profile of benapenem in humans and mice. Monte Carlo simulations were employed to determine the cutoff values and the appropriate benapenem dosing regimens for the treatment of infections caused by clinical isolates of Enterobacteriaceae. Two 2-compartment models were developed to describe the PK profiles of benapenem in humans and mice. A two-site binding model was applied to fit the protein binding in mouse plasma. Through correlation analysis, the percentage of the time that the free drug concentration remains above the MIC (%fT>MIC) was determined to be the indicator of efficacy. Results from the simulation showed that the probability of target attainment (PTA) against the tested isolates was over 90% with the dosing regimens studied. The PK/PD cutoff value of benapenem was 1 mg/liter at a %fT>MIC of 60% when given at a dose of 1,000 mg/day by i.v. drip for 0.5 h. The established model provides a better understanding of the pharmacological properties of benapenem for the treatment of Enterobacteriaceae infections. The proposed PK/PD cutoff value suggests that benapenem is a promising antibacterial against the Enterobacteriaceae. The cutoff value of 1 mg/liter may be a useful guide for the clinical use of benapenem and for surveillance for benapenem resistance.

[1]  W. Craig,et al.  In vivo pharmacodynamics of lefamulin, the first systemic pleuromutilin for human use, in a neutropenic murine thigh infection model , 2019, The Journal of antimicrobial chemotherapy.

[2]  JJ Wilkins,et al.  Thoughtflow: Standards and Tools for Provenance Capture and Workflow Definition to Support Model‐Informed Drug Discovery and Development , 2017, CPT: pharmacometrics & systems pharmacology.

[3]  S. Marshall,et al.  Good Practices in Model‐Informed Drug Discovery and Development: Practice, Application, and Documentation , 2016, CPT: pharmacometrics & systems pharmacology.

[4]  Alicia Rodríguez-Gascón,et al.  Applications of the pharmacokinetic/pharmacodynamic (PK/PD) analysis of antimicrobial agents. , 2015, Journal of infection and chemotherapy : official journal of the Japan Society of Chemotherapy.

[5]  K. Venkatakrishnan,et al.  Optimizing Oncology Therapeutics Through Quantitative Translational and Clinical Pharmacology: Challenges and Opportunities , 2015, Clinical pharmacology and therapeutics.

[6]  A. Oliver,et al.  Breakpoints for carbapenemase-producing Enterobacteriaceae: is the problem solved? , 2014, Enfermedades infecciosas y microbiologia clinica.

[7]  M. Balík,et al.  Pharmacokinetics of imipenem in critically ill patients during empirical treatment of nosocomial pneumonia: a comparison of 0.5-h and 3-h infusions. , 2014, International journal of antimicrobial agents.

[8]  R J Keizer,et al.  Modeling and Simulation Workbench for NONMEM: Tutorial on Pirana, PsN, and Xpose , 2013, CPT: pharmacometrics & systems pharmacology.

[9]  Udo Albus,et al.  Book Review: Guide for the Care and use of Laboratory Animals , 1998 .

[10]  W. Craig,et al.  In Vivo Pharmacodynamics of New Lipopeptide MX-2401 , 2010, Antimicrobial Agents and Chemotherapy.

[11]  B. Congeni.  Ertapenem , 2010, Reactions Weekly.

[12]  T. Nabeshima,et al.  Population pharmacokinetic analysis of vancomycin in patients with gram‐positive infections and the influence of infectious disease type , 2009, Journal of clinical pharmacy and therapeutics.

[13]  D. Nicolau.  Pharmacokinetic and pharmacodynamic properties of meropenem. , 2008, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[14]  C. Frei,et al.  Antimicrobial breakpoints for gram-negative aerobic bacteria based on pharmacokinetic-pharmacodynamic models with Monte Carlo simulation. , 2008, The Journal of antimicrobial chemotherapy.

[15]  Kaori Tanaka,et al.  [Efficacy of injectable carbapenems for respiratory infections caused by Streptococcus pneumoniae and Haemophilus influenzae with Monte Carlo simulation]. , 2007, The Japanese journal of antibiotics.

[16]  M. Grant,et al.  Penetration of ertapenem into skeletal muscle and subcutaneous adipose tissue in healthy volunteers measured by in vivo microdialysis. , 2006, The Journal of antimicrobial chemotherapy.

[17]  G. Drusano,et al.  Comparative Pharmacokinetics and Pharmacodynamic Target Attainment of Ertapenem in Normal-Weight, Obese, and Extremely Obese Adults , 2006, Antimicrobial Agents and Chemotherapy.

[18]  E. Niclas Jonsson,et al.  PsN-Toolkit - A collection of computer intensive statistical methods for non-linear mixed effect modeling using NONMEM , 2005, Comput. Methods Programs Biomed..

[19]  U. Holzgrabe,et al.  Evaluation by Monte Carlo Simulation of the Pharmacokinetics of Two Doses of Meropenem Administered Intermittently or as a Continuous Infusion in Healthy Volunteers , 2005, Antimicrobial Agents and Chemotherapy.

[20]  M. Kurowski,et al.  Ertapenem Pharmacokinetics and Impact on Intestinal Microflora, in Comparison to Those of Ceftriaxone, after Multiple Dosing in Male and Female Volunteers , 2004, Antimicrobial Agents and Chemotherapy.

[21]  George L. Drusano,et al.  Antimicrobial pharmacodynamics: critical interactions of 'bug and drug' , 2004, Nature Reviews Microbiology.

[22]  P. Deutsch,et al.  Pharmacokinetics of Total and Unbound Ertapenem in Healthy Elderly Subjects , 2004, Antimicrobial Agents and Chemotherapy.

[23]  D. Nicolau,et al.  Use of Monte Carlo Simulation to Design an Optimized Pharmacodynamic Dosing Strategy for Meropenem , 2003, Journal of clinical pharmacology.

[24]  S. Waldman,et al.  Pharmacokinetics of Intramuscularly Administered Ertapenem , 2003, Antimicrobial Agents and Chemotherapy.

[25]  G L Drusano,et al.  Prevention of resistance: a goal for dose selection for antimicrobial agents. , 2003, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[26]  S. Waldman,et al.  Pharmacokinetics of Ertapenem in Healthy Young Volunteers , 2002, Antimicrobial Agents and Chemotherapy.

[27]  L. Benet,et al.  Changes in plasma protein binding have little clinical relevance , 2002, Clinical pharmacology and therapeutics.

[28]  T. Vondracek,et al.  Beta-Lactam Antibiotics: Is Continuous Infusion The Preferred Method of Administration? , 1995, The Annals of pharmacotherapy.

[29]  H. Rosenthal.  A graphic method for the determination and presentation of binding parameters in a complex system. , 1967, Analytical biochemistry.

[30]  Guideline on the use of pharmacokinetics and pharmacodynamics in the development of antimicrobial medicinal products , 2016 .

[31]  Lloyd H. Michael,et al.  The Guide for the Care and Use of Laboratory Animals. , 2016, ILAR journal.

[32]  X. Lu.  Pharmacodynamic evaluation of benapenem,a new carbapenem antibiotic,in mouse urinary tract infection model , 2015 .

[33]  E N Jonsson,et al.  Xpose--an S-PLUS based population pharmacokinetic/pharmacodynamic model building aid for NONMEM. , 1999, Computer methods and programs in biomedicine.

[34]  W. Craig,et al.  Pharmacokinetic/pharmacodynamic Parameters: Rationale for Antibacterial Dosing of Mice and Men Tions Were Associated with Only a Slight Reduction in Bacterial , 2022 .